BCYC BICYCLE THERAPEUTICS PLC revenue, earnings and financials

For the quarter ended June 30, 2026, BICYCLE THERAPEUTICS PLC reported revenue of $629K (down 78.5% from a year earlier), net income of −$50.3M and diluted EPS of −$0.72; over the last four quarters revenue was $61.2M and net income −$190M; for the fiscal year ended December 2025 revenue was $72.6M, up 105.8% on the year before.

BCYC annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $72.6M, gross profit n/a, operating income −$247M, net income −$219M (margin -301.7%), EPS −$3.16
• Fiscal year ended Dec 2024: revenue $35.3M, gross profit n/a, operating income −$210M, net income −$169M (margin -479.2%), EPS −$2.90
• Fiscal year ended Dec 2023: revenue $27.0M, gross profit n/a, operating income −$190M, net income −$181M (margin -669.7%), EPS −$5.08
• Fiscal year ended Dec 2022: revenue $14.5M, gross profit n/a, operating income −$117M, net income −$113M (margin -779.3%), EPS −$3.80
• Fiscal year ended Dec 2021: revenue $11.7M, gross profit n/a, operating income −$65.6M, net income −$66.8M (margin -571.2%), EPS −$2.67

BCYC quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $629K (down 78.5% year over year), net income −$50.3M, EPS −$0.72
• Quarter ended Mar 31, 2026: revenue $887K (down 91.1% year over year), net income −$60.8M, EPS −$0.87
• Quarter ended Dec 31, 2025 (from the annual report): revenue $48.0M (up 1193.3% year over year), net income −$20.2M, EPS −$0.29
• Quarter ended Sep 30, 2025: revenue $11.7M (up 338.5% year over year), net income −$59.1M, EPS −$0.85
• Quarter ended Jun 30, 2025: revenue $2.92M (down 68.8% year over year), net income −$79.0M, EPS −$1.14
• Quarter ended Mar 31, 2025: revenue $9.98M (down 48.9% year over year), net income −$60.8M, EPS −$0.88
• Quarter ended Dec 31, 2024 (from the annual report): revenue $3.71M (down 30.4% year over year), net income −$51.9M, EPS −$0.77
• Quarter ended Sep 30, 2024: revenue $2.68M (down 50.0% year over year), net income −$50.8M, EPS −$0.74
• Quarter ended Jun 30, 2024: revenue $9.36M (down 17.9% year over year), net income −$39.8M, EPS −$0.77
• Quarter ended Mar 31, 2024: revenue $19.5M (up 298.9% year over year), net income −$26.6M, EPS −$0.62
• Quarter ended Dec 31, 2023 (from the annual report): revenue $5.33M (up 67.4% year over year), net income −$49.1M, EPS −$1.11
• Quarter ended Sep 30, 2023: revenue $5.35M (up 76.1% year over year), net income −$49.9M, EPS −$1.26
• Quarter ended Jun 30, 2023: revenue $11.4M (up 160.3% year over year), net income −$42.6M, EPS −$1.41
• Quarter ended Mar 31, 2023: revenue $4.90M (up 26.8% year over year), net income −$39.1M, EPS −$1.30
• Quarter ended Dec 31, 2022 (from the annual report): revenue $3.19M (down 15.5% year over year), net income −$30.0M, EPS −$1.01
• Quarter ended Sep 30, 2022: revenue $3.04M (down 29.8% year over year), net income −$28.3M, EPS −$0.96
• Quarter ended Jun 30, 2022: revenue $4.38M (up 145.3% year over year), net income −$26.8M, EPS −$0.90
• Quarter ended Mar 31, 2022: revenue $3.86M (up 113.5% year over year), net income −$27.6M, EPS −$0.93
• Quarter ended Dec 31, 2021 (from the annual report): revenue $3.77M, net income −$18.0M, EPS −$0.61
• Quarter ended Sep 30, 2021: revenue $4.33M, net income −$14.7M, EPS −$0.59

BCYC cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$250M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow −$165M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$60.6M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$86.1M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2021: operating cash flow −$14.8M, share buybacks n/a, dividends $0.00 per share

BCYC balance sheet

• Jun 30, 2026: cash $510M, total assets $607M, total liabilities $96.3M, shareholders' equity $510M
• Mar 31, 2026: cash $559M, total assets $652M, total liabilities $98.1M, shareholders' equity $554M
• Dec 31, 2025: cash $628M, total assets $718M, total liabilities $108M, shareholders' equity $610M
• Sep 30, 2025: cash $648M, total assets $764M, total liabilities $145M, shareholders' equity $618M
• Jun 30, 2025: cash $721M, total assets $832M, total liabilities $163M, shareholders' equity $669M
• Mar 31, 2025: cash $793M, total assets $884M, total liabilities $144M, shareholders' equity $740M
• Dec 31, 2024: cash $880M, total assets $957M, total liabilities $164M, shareholders' equity $793M
• Sep 30, 2024: cash $891M, total assets $997M, total liabilities $166M, shareholders' equity $831M

What is BCYC's revenue?

BICYCLE THERAPEUTICS PLC reported $61.2M of revenue over its last four quarters, through June 30, 2026.

Is BCYC profitable?

No. BICYCLE THERAPEUTICS PLC lost $190M over the last four quarters.

What is BCYC's EPS?

Diluted earnings per share over the last four quarters were −$2.73; −$0.72 in the latest quarter.

BCYC ownership and insider trades · All stocks